Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥6,265 JPY
Change Today +17.00 / 0.27%
Volume 1.5M
As of 1:10 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥6,280
Previous Close
¥6,248
Day High
¥6,307
Day Low
¥6,211
52 Week High
03/6/15 - ¥6,657
52 Week Low
10/17/14 - ¥4,338
Market Cap
4.9T
Average Volume 10 Days
2.3M
EPS TTM
¥67.66
Shares Outstanding
789.9M
EX-Date
03/27/15
P/E TM
92.6x
Dividend
¥180.00
Dividend Yield
2.88%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: ¥387.0M
Chief Medical & Scientific Officer, Director ...
Total Annual Compensation: ¥332.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Announces Research Collaboration with Keio University School of Medicine and Niigata University

Takeda Pharmaceutical Company Limited announced that it has signed an agreement to undertake collaborative research with Keio University School of Medicine and Niigata University at Takedas Shonan Research Center regarding the search for and functional analysis of disease-related RNA-binding proteins. This may lead to treatments in the areas such as CNS and oncology. This collaboration focuses on disease-related RNA-binding proteins, and is scheduled to last three years, with Professor Hideyuki Okano of the Physiology Laboratory at Keio University School of Medicine directing the overall research, with Associate Professor Masato Yano from Niigata University participating as well. This research collaboration will focus on the systematic and comprehensive study of RNA-binding proteins, with the aim of creating new therapeutic target candidates and game-changing technologies for drug discovery.

Center for iPS Cell Research Application and Takeda Pharmaceutical Company Limited to Work Together to Develop Clinical Applications of Induced Pluripotent Stem Cells in Areas Such as Heart Failure, Diabetes Mellitus, Neurological Disorders and Cancer Immunotherapy

Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA Joint Program for iPS Cell Applications" (T-CiRA) is designed to expedite multiple research projects for drug discovery and cell therapy using iPS cells. CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the Program, while Takeda provides long-term funding, recommendations on research management, and facilities at its Shonan Research Center, Fujisawa, Japan. iPS cell technologies have the potential to bring about ground-breaking transformations to future medical treatments, and their applications span a variety of fields, including drug discovery, cell therapy and drug safety assessments. During a period of 10 years, Takeda and CiRA will jointly run projects led by research experts invited from CiRA. The collaboration is expected to make significant contributions to the science and application of iPS cell technology into clinical practice, which requires a significant amount of time, effort and investment. This collaboration is aligned with the purpose of National Projects of Japan on clinical applications of iPS cell technologies. Takeda will provide research facilities at its Shonan Research Center and collaborative funding of ¥20 billion over a 10-year period. In addition, Takeda will provide more than ¥12 billion worth of research support (facility, equipment, Takeda researchers and various research services) over the 10-year collaboration period. About 100 researchers including new researchers recruited globally are to be based at Takeda'sShonan Research Center engaged in joint research, with each contributing about 50 researchers. Also, the access to special research assets, such as Takeda's compound libraries, will be provided for the collaboration. Potential initial research projects include heart failure, diabetes mellitus, neuro-psychiatric disorders, and cancer immunotherapy. Additional projects will be included as the collaboration moves forward. Once set up, around 10 projects will be pursued concurrently.

FDA Advisory Committee Reviews Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceutical Company Limited Alogliptin Examine Cardiovascular Safety Outcomes Trial

Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceutical Company Limited announced that members of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States (U.S.) Food and Drug Administration (FDA) convened to review one of the first cardiovascular (CV) outcomes trials (CVOT) in patients with Type 2 diabetes, EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome). The Committee voted that, based on the data presented, the results of EXAMINE demonstrate that the use of alogliptin in patients with Type 2 diabetes has an acceptable CV risk profile. All 16 voting members of the Committee supported this recommendation. In addition, 13 out of 16 Committee members voted that safety information from the EXAMINE study should be added to the alogliptin labeling and the other three members voted for no change to the labeling. EXAMINE, a large, randomized, double-blind, placebo-controlled outcomes study, was completed as a result of the U.S. FDA 2008 Guidance, titled "Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," for all Type 2 diabetes treatments under development since the issuance of the guidance. The EXAMINE trial was designed to evaluate CV safety following treatment with alogliptin in addition to standard of care, versus placebo in addition to standard of care, in patients with Type 2 diabetes who were at high risk for major adverse cardiovascular events (MACE) due to recent acute coronary syndrome (ACS). The trial's primary objective was to evaluate non-inferiority of CV risk based on a primary composite endpoint of CV death, nonfatal myocardial infarction (MI) and nonfatal stroke. The FDA also asked the Committee to discuss whether additional alogliptin studies are needed and to make any recommendations regarding the evaluation of the risk-benefit profile for alogliptin. In addition to discussing EXAMINE's pre-specified primary CV outcome data, the Committee discussed other study analyses including heart failure, study data by geographic region, and other data including renal safety findings. The outcome of the Advisory Committee meeting is non-binding and will be taken into consideration by the FDA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,263.00 JPY +15.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.49 USD -0.83
Baxter International Inc $70.37 USD -0.77
Becton Dickinson and Co $142.04 USD -2.29
Biogen Inc $389.27 USD -12.44
Merck KGaA €105.68 EUR +0.71
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 65.8x
Price/Sales 2.8x
Price/Book 2.0x
Price/Cash Flow 14.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.